摘要: Several options are available today in the treatment of advanced colorectal cancer: traditional chemotherapeutic regimens, targeted therapies, and their combinations. Panitumumab is a new, fully human anti-EGFR monoclonal antibody, what well-tolerated, effective as single agent chemotherapy refractory patients different The clinical response restricted to tumors with wild-type RAS, therefore RAS status should be checked before treatment.
springer.com
sci-hub.se 参考文章(39)
R. Arends, B. B. Yang, G. Schwab, P. Lockbaum, C. Funelas, L. Roskos, Flexible dosing schedules of panitumumab (ABX-EGF) in cancer patients Journal of Clinical Oncology. ,vol. 23, pp. 3089- 3089 ,(2005) , 10.1200/JCO.2005.23.16_SUPPL.3089
J. Randolph Hecht, Edith Mitchell, Tarek Chidiac, Carroll Scroggin, Christopher Hagenstad, David Spigel, John Marshall, Allen Cohn, David McCollum, Philip Stella, Robert Deeter, Seta Shahin, Rafael G. Amado, A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer Journal of Clinical Oncology. ,vol. 27, pp. 672- 680 ,(2009) , 10.1200/JCO.2008.19.8135
Kenneth A Foon, Xiao-Dong Yang, Louis M Weiner, Arie S Belldegrun, Robert A Figlin, Jeffrey Crawford, Eric K Rowinsky, Janice P Dutcher, Nicholas J Vogelzang, Jared Gollub, John A Thompson, Garry Schwartz, Ronald M Bukowski, Lorin K Roskos, Gisela M Schwab, Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody International Journal of Radiation Oncology Biology Physics. ,vol. 58, pp. 984- 990 ,(2004) , 10.1016/J.IJROBP.2003.09.098
M. Peeters, T. Price, Y. Hotko, A. Cervantes, M. Ducreux, T. André, E. Chan, F. Lordick, A. Rong, J. Gansert, 14LBA Randomized phase 3 study of panitumumab with FOLFIRI vs FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC) Ejc Supplements. ,vol. 7, pp. 10- ,(2009) , 10.1016/S1359-6349(09)72049-X
Aya Jakobovits, Rafael G Amado, Xiaodong Yang, Lorin Roskos, Gisela Schwab, From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice Nature Biotechnology. ,vol. 25, pp. 1134- 1143 ,(2007) , 10.1038/NBT1337
Hans Prenen, Jef De Schutter, Bart Jacobs, Wendy De Roock, Bart Biesmans, Bart Claes, Diether Lambrechts, Eric Van Cutsem, Sabine Tejpar, PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. Clinical Cancer Research. ,vol. 15, pp. 3184- 3188 ,(2009) , 10.1158/1078-0432.CCR-08-2961
Toshihiko Doi, Atsushi Ohtsu, Makoto Tahara, Tomohide Tamura, Kuniaki Shirao, Yasuhide Yamada, Satoru Otani, Bing-Bing Yang, Masayuki Ohkura, Tomoko Ohtsu, Safety and pharmacokinetics of panitumumab in Japanese patients with advanced solid tumors International Journal of Clinical Oncology. ,vol. 14, pp. 307- 314 ,(2009) , 10.1007/S10147-008-0855-2
Ludovic Barault, Nicolas Veyrie, Valerie Jooste, Delphine Lecorre, Caroline Chapusot, Jean-Marc Ferraz, Astrid Lièvre, Marion Cortet, Anne-Marie Bouvier, Patrick Rat, Patrick Roignot, Jean Faivre, Pierre Laurent-Puig, Francoise Piard, Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers International Journal of Cancer. ,vol. 122, pp. 2255- 2259 ,(2008) , 10.1002/IJC.23388
J. Douillard, S. Siena, J. Cassidy, J. Tabernero, R. Burkes, M.E. Barugel, Y. Humblet, D. Cunningham, M. Wolf, J.L. Gansert, 10LBA Randomized phase 3 study of panitumumab with FOLFOX4 compared to FOLFOX4 alone as 1st-line treatment (tx) for metastatic colorectal cancer (mCRC): the PRIME trial Ejc Supplements. ,vol. 7, pp. 6- ,(2009) , 10.1016/S1359-6349(09)72039-7
Salvatore Artale, Andrea Sartore-Bianchi, Silvio Marco Veronese, Valentina Gambi, Carolina Silvia Sarnataro, Marcello Gambacorta, Calogero Lauricella, Salvatore Siena, Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. Journal of Clinical Oncology. ,vol. 26, pp. 4217- 4219 ,(2008) , 10.1200/JCO.2008.18.7286